Jobs
View more job listings or post a job
PTC Therapeutics Scientist I - Translational Omics
Applied BioMath Quantitative Systems Pharmacology Modeler - Project Lead/Group Lead
Sorrento Therapetuics Scientist/Sr. Scientist -- protein/gene characterization, LC-MS
Applied BioMath Senior Scientist - Pharmacometrics
Applied BioMath Senior Scientist - Mathematical Modeler
Evotec Senior Scientist
UC Davis - California Animal Health and Food Safety Laboratory TOXICOLOGY SECTION: LAB RESEARCH SUPERVISOR 2/GROUP LEADER (LAB RSCH SUPV 2)
Catalent Pharma Solutions Scientist - Molecular Biology / Protein Expression
Catalent Pharma Solutions Associate Scientist - Molecular Biology / Protein Expression
Protagonist Therapeutics CLINICAL PHARMACOLOGIST
Post a job

Seminar luncheon

Developing Relevant Human Neural In Vitro Assays for CNS Safety Assessment and Drug Discovery: Challenges and Perspectives


Speakers: Jonathan Davila PhD., CEO / Co-Founder, NeuCyte Inc.
Organizers:
Date: 2017-07-28
Time: 11:00-13:30 Pacific Time
Registration fee: (USD): Food: $0.
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (1)Cellular Dynamics Intl
Vendor show vendors registered to date: (5)Agilent; BioLegend; Cyprotex; JL Powers & Co; Thermo Fisher Scientific, SID
Registration: http://www.PBSS.org
Registration deadline:2017-07-26  (it will close sooner if the seating cap is reached)

About the Topic

High attrition rates of novel CNS drugs indicate that current preclinical testing is largely insufficient to support development of urgently needed therapies for millions of patients. iPSC technology and rapidly improving methods to generate functional human tissues offer new opportunities to develop novel disease relevant cell-based assays. This approach comes with high expectations but also presents many challenges. NeuCyte develops human neural in vitro platforms uniquely suited for assessing relevant complex  electrophysiology readouts allowing for more reliable prediction of drug efficacy, CNS safety, and identification of neurotoxicity. In this presentation, we will provide an overview of critical considerations that need to be taken when developing human iPSC derived neural in vitro assays. 


2021-05-26, [Free Online Workshop] Antibody-Drug Conjugates: Discovery to Development
2021-06-23, [Free Online Symposium] Highlights from 2020's FDA New Drug Approvals (jointly by PBSS and CLSA)
2021-07-29, [Free Online Symposium] Development of Inhalation Therapeutics (jointly by AAPS-BADG / PBSS / Genentech)
2021-09-23, [Free Online Symposium] Drug-Drug Interaction - Industry Trends and the 2020 FDA Guidances
┬ęPharmaceutical & BioScience Society, International; Last Modified: 5/10/2021; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Hypha Discovery Synthesis, purification & NMR characterization of drug metabolites at mg-g scale with COAs, including CYP/AOX/FMO metabolites, glucuronides & sulfates
Eurofins Selcia 14C Custom Radiolabelling for pre-clinical studies (ADME, drug metabolism, QWBA) and GMP 14C-API for hAME, clinical mass balance /micro-dosing.
Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad